Regeneron Pharmaceuticals, Inc. (REGN) Key Metrics
REGN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $81.41B
- Enterprise value
- $77.26B
- P/E (TTM)
- 19.6 10-yr median 18.7
- Forward P/E
- 14.5
- PEG ratio
- 1.32
- Price / sales
- 5.2 10-yr median 6.5
- Price / book
- 2.6 10-yr median 3.9
- EV / EBITDA
- 13.1 10-yr median 14.6
- Dividend yield
- 0.47% $3.76 a year
- Beta
- 0.15
REGN key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsREGN valuation Price multiples at each fiscal year-end price.
REGN returns How much profit the business earns on the capital it uses.
REGN per-share figures Results divided by the shares outstanding at year-end.
REGN financial health Debt, liquidity and how easily interest is covered.
REGN efficiency & capital use Working capital cycle and where the cash goes.
REGN valuation history
REGN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
REGN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
REGN cash returned to shareholders
REGN price vs earnings per share
REGN key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $83.83B | $81.99B | $99.86B | $81.89B | $70.86B | $55.61B | $43.03B | $42.88B | $43.58B | $42.69B |
| Enterprise value | $77.93B | $75.68B | $91.72B | $76.85B | $67.86B | $52.49B | $40.53B | $39.11B | $41.85B | $42.14B |
| P/E ratio | 18.6 | 18.6 | 25.3 | 18.9 | 8.8 | 15.8 | 20.3 | 17.5 | 36.4 | 47.7 |
| Price / sales | 5.8 | 5.8 | 7.6 | 6.7 | 4.4 | 6.5 | 5.5 | 6.4 | 7.4 | 8.8 |
| Price / book | 2.7 | 2.8 | 3.8 | 3.6 | 3.8 | 5.0 | 3.9 | 4.9 | 7.1 | 9.6 |
| Price / free cash flow | 20.5 | 22.4 | 27.2 | 18.5 | 10.9 | 27.8 | 21.5 | 23.7 | 42.1 | 43.8 |
| Price / operating cash flow | 16.8 | 18.5 | 21.7 | 16.3 | 10.0 | 21.2 | 17.7 | 19.5 | 33.3 | 28.7 |
| EV / sales | 5.4 | 5.3 | 7.0 | 6.3 | 4.2 | 6.2 | 5.2 | 5.8 | 7.1 | 8.7 |
| EV / EBITDA | 13.4 | 14.2 | 22.7 | 14.6 | 7.0 | 12.8 | 16.7 | 14.6 | 18.8 | 29.4 |
| EV / free cash flow | 19.1 | 20.7 | 25.0 | 17.4 | 10.4 | 26.2 | 20.3 | 21.6 | 40.5 | 43.3 |
| Earnings yield | 5.4% | 5.4% | 4.0% | 5.3% | 11.4% | 6.3% | 4.9% | 5.7% | 2.8% | 2.1% |
| Free cash flow yield | 4.9% | 4.5% | 3.7% | 5.4% | 9.2% | 3.6% | 4.6% | 4.2% | 2.4% | 2.3% |
| Dividend yield | 0.4% | 0.0% | 0.0% | — | — | — | — | — | 0.8% | 1.2% |
| Shareholder yield (dividends + buybacks) | 5.2% | 4.4% | 2.2% | 3.1% | 3.8% | 11.7% | 1.1% | 0.4% | 1.5% | 1.5% |
| Share price at fiscal year-end | $771.87 | $712.33 | $878.29 | $721.49 | $631.52 | $483.11 | $375.48 | $373.50 | $375.96 | $367.09 |
| Per share | ||||||||||
| Revenue per share | $132.07 | $123.39 | $115.37 | $107.25 | $143.24 | $73.82 | $68.62 | $58.46 | $50.66 | $41.79 |
| Earnings per share | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 |
| Operating cash flow per share | $45.85 | $38.41 | $40.40 | $44.18 | $63.11 | $22.75 | $21.20 | $19.12 | $11.28 | $12.78 |
| Free cash flow per share | $37.57 | $31.84 | $32.26 | $38.99 | $58.19 | $17.41 | $17.46 | $15.78 | $8.93 | $8.37 |
| Cash per share | $79.24 | $78.30 | $95.38 | $68.21 | $50.75 | $58.41 | $28.05 | $39.76 | $24.99 | $8.93 |
| Book value per share | $287.82 | $255.03 | $228.44 | $199.68 | $167.28 | $95.79 | $96.77 | $76.28 | $53.01 | $38.26 |
| Tangible book value per share | $276.24 | $245.05 | $219.30 | $191.62 | $228.22 | $95.79 | $96.77 | $76.28 | $53.01 | $38.26 |
| Dividends per share | $3.41 | $0.00 | $0.00 | — | — | — | — | — | $3.09 | $4.30 |
| Capex per share | $8.27 | $6.57 | $8.15 | $5.20 | $4.92 | $5.34 | $3.75 | $3.34 | $2.35 | $4.40 |
| Debt per share | $24.92 | $23.50 | $23.77 | $23.80 | $24.06 | $31.36 | $6.23 | $6.96 | $10.11 | $4.14 |
| Shares outstanding | 108.6M | 115.1M | 113.7M | 113.5M | 112.2M | 115.1M | 114.6M | 114.8M | 115.9M | 116.3M |
| Change in shares outstanding | −5.6% | +1.2% | +0.2% | +1.2% | −2.5% | +0.4% | −0.2% | −1.0% | −0.3% | +0.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 14.9% | 16.0% | 16.3% | 20.9% | 54.2% | 31.8% | 21.3% | 32.8% | 22.6% | 22.1% |
| Return on invested capital (ROIC) | 12.7% | 18.0% | 21.5% | 28.8% | 65.4% | 40.0% | 28.3% | 51.6% | 28.9% | 26.8% |
| Return on assets (ROA) | 11.5% | 12.5% | 12.7% | 15.9% | 37.9% | 22.0% | 15.9% | 23.8% | 15.2% | 14.2% |
| Return on tangible assets | 11.5% | 12.1% | 12.3% | 15.3% | 25.0% | 20.5% | 14.3% | 20.8% | 13.7% | 12.8% |
| Free cash flow margin | 28.4% | 25.8% | 28.0% | 36.3% | 40.6% | 23.6% | 25.4% | 27.0% | 17.6% | 20.0% |
| Income quality (OCF / net income) | 1.11 | 1.00 | 1.16 | 1.16 | 0.88 | 0.75 | 1.15 | 0.90 | 1.09 | 1.66 |
| Financial health | ||||||||||
| Total debt | $2.71B | $2.70B | $2.70B | $2.70B | $2.70B | $3.61B | $713.9M | $799.3M | $1.17B | $481.1M |
| Cash & short-term investments | $8.61B | $9.01B | $10.84B | $7.74B | $5.69B | $6.72B | $3.21B | $4.56B | $2.90B | $1.04B |
| Net debt | −$5.90B | −$6.31B | −$8.14B | −$5.04B | −$3.00B | −$3.11B | −$2.50B | −$3.77B | −$1.72B | −$557.6M |
| Debt / equity | 0.09 | 0.09 | 0.10 | 0.12 | 0.14 | 0.33 | 0.06 | 0.09 | 0.19 | 0.11 |
| Debt / assets | 0.07 | 0.07 | 0.08 | 0.09 | 0.11 | 0.21 | 0.05 | 0.07 | 0.13 | 0.07 |
| Net debt / EBITDA | −1.01 | −1.19 | −2.01 | −0.96 | −0.31 | −0.76 | −1.03 | −1.40 | −0.77 | −0.39 |
| Current ratio | 4.13 | 4.73 | 5.69 | 5.06 | 3.56 | 4.54 | 3.67 | 5.89 | 5.79 | 3.15 |
| Quick ratio | 3.39 | 3.95 | 4.94 | 4.29 | 3.07 | 3.86 | 2.99 | 5.04 | 5.03 | 2.83 |
| Interest coverage | 81.7 | 72.3 | 55.4 | 90.7 | 156.1 | 62.9 | 73.2 | 89.9 | 82.8 | 185.0 |
| Working capital | $13.65B | $14.72B | $16.06B | $12.74B | $10.08B | $9.95B | $5.59B | $6.61B | $4.63B | $2.67B |
| Invested capital | $25.36B | $23.05B | $17.83B | $17.62B | $15.77B | $7.91B | $8.59B | $4.99B | $4.42B | $3.89B |
| Tangible asset value | $30.00B | $28.20B | $24.93B | $21.75B | $25.61B | $11.03B | $11.09B | $8.76B | $6.14B | $4.45B |
| Net current asset value | $8.72B | $10.26B | $12.37B | $9.33B | $7.35B | $6.62B | $3.97B | $4.98B | $2.98B | $1.39B |
| Graham number | $518.29 | $469.02 | $422.76 | $414.41 | $520.47 | $256.49 | $200.50 | $191.17 | $111.05 | $81.41 |
| Graham net-net per share | $47.97 | $59.16 | $81.60 | $56.29 | $40.39 | $40.22 | $20.03 | $33.50 | $18.29 | −$0.66 |
| Capital allocation | ||||||||||
| Dividends paid | $370.3M | $0 | $0 | — | — | — | — | — | $358.7M | $500.2M |
| Share buybacks (net) | $3.97B | $3.63B | $2.23B | $2.53B | $2.68B | $6.53B | $463.9M | $191.6M | $301.7M | $143.2M |
| Dividend payout ratio | 8.2% | 0.0% | 0.0% | — | — | — | — | — | 29.9% | 55.9% |
| Dividends + buybacks / free cash flow | 106.4% | 99.1% | 60.9% | 57.1% | 41.0% | 325.8% | 23.2% | 10.6% | 63.8% | 66.1% |
| Capex / revenue | 6.3% | 5.3% | 7.1% | 4.8% | 3.4% | 7.2% | 5.5% | 5.7% | 4.6% | 10.5% |
| Capex / operating cash flow | 18.0% | 17.1% | 20.2% | 11.8% | 7.8% | 23.5% | 17.7% | 17.5% | 20.9% | 34.5% |
| Capex / depreciation | 1.65 | 1.57 | 2.20 | 1.73 | 1.93 | 2.61 | 2.04 | 2.59 | 1.87 | 4.89 |
| Stock-based compensation / revenue | 6.9% | 6.9% | 6.7% | 6.0% | 3.7% | 5.1% | 5.9% | 6.4% | 8.6% | 11.5% |
| R&D / revenue | 40.8% | 36.8% | 33.8% | 25.1% | 16.3% | 29.4% | 38.6% | 32.6% | 35.3% | 42.2% |
| SG&A / revenue | 18.8% | 20.8% | 19.5% | 17.4% | 11.4% | 15.8% | 23.3% | 23.2% | 22.5% | 24.2% |
| Efficiency | ||||||||||
| Days sales outstanding | 152.1 | 152.7 | 153.0 | 170.4 | 115.3 | 148.2 | 116.7 | 114.7 | 111.4 | 115.6 |
| Days of inventory on hand | 546.3 | 524.9 | 1,029.0 | 465.9 | 259.2 | 448.5 | 598.9 | 789.3 | 517.3 | 388.5 |
| Days payables outstanding | 150.2 | 129.3 | 247.0 | 123.4 | 69.7 | 120.3 | 148.5 | 166.6 | 143.9 | 168.0 |
| Cash conversion cycle (days) | 548.2 | 548.3 | 935.0 | 512.9 | 304.8 | 476.4 | 567.1 | 737.3 | 484.8 | 336.1 |
| Receivables turnover | 2.40 | 2.39 | 2.39 | 2.14 | 3.17 | 2.46 | 3.13 | 3.18 | 3.28 | 3.16 |
| Payables turnover | 2.43 | 2.82 | 1.48 | 2.96 | 5.24 | 3.03 | 2.46 | 2.19 | 2.54 | 2.17 |
| Inventory turnover | 0.67 | 0.70 | 0.35 | 0.78 | 1.41 | 0.81 | 0.61 | 0.46 | 0.71 | 0.94 |
| Asset turnover | 0.37 | 0.40 | 0.42 | 0.45 | 0.75 | 0.53 | 0.59 | 0.65 | 0.75 | 0.77 |
| Average receivables | $5.98B | $5.94B | $5.50B | $5.68B | $5.08B | $3.45B | $2.51B | $2.11B | $1.79B | $1.54B |
| Average payables | $864.2M | $698.0M | $597.9M | $576.6M | $519.8M | $446.8M | $318.1M | $198.2M | $156.6M | $138.0M |
| Average inventory | $3.14B | $2.83B | $2.49B | $2.18B | $1.93B | $1.67B | $1.28B | $938.7M | $562.7M | $319.0M |
| Intangibles / total assets | 3.1% | 3.0% | 3.1% | 3.1% | −26.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from REGN's annual financial statements (latest annual report filed February 4, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
REGN valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Regeneron traded at 18.6 times earnings, against a 10-year median of 18.7. Based on the latest twelve months, the trailing P/E is 19.6 and the forward P/E is 14.5. Regeneron earned a return on equity of 14.9% and a return on invested capital of 12.7% in fiscal 2025. It ended the year with $2.7 billion of debt and $8.6 billion in cash and short-term investments, a net cash position of $5.9 billion. It returned $4.3 billion to shareholders: $370.3 million in dividends and $4.0 billion in share buybacks, 106% of free cash flow. The share count fell 6.6% from 116.3M to 108.6M over 9 years.
See the REGN income statement, the REGN chart for price history, or the REGN stock overview for the latest quote and news.
REGN key metrics FAQ
What is Regeneron's P/E ratio?
Regeneron's trailing P/E ratio is 19.6 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 14.5. At the end of fiscal 2025 it was 18.6, compared with a 10-year median of 18.7.
What is Regeneron's EV/EBITDA?
Regeneron's enterprise value was 13.4 times EBITDA at the end of fiscal 2025 (enterprise value $77.9 billion, EBITDA $5.8 billion); the current EV/EBITDA is 13.1.
What is Regeneron's return on equity?
Regeneron's return on equity (ROE) was 14.9% in fiscal 2025: net income of $4.5 billion on average shareholders' equity of $30.3 billion.
What is Regeneron's ROIC?
Regeneron's return on invested capital was 12.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Regeneron have?
Regeneron had total debt of $2.7 billion at the end of fiscal 2025, a debt-to-equity ratio of 0.09 and more cash than debt.
What is Regeneron's dividend yield?
Regeneron's forward dividend yield is 0.47%. Regeneron paid $370.3 million in dividends in fiscal 2025 ($3.41 per share), a payout ratio of 8.2%.
Does Regeneron buy back its shares?
Yes. Regeneron spent $4.0 billion on net share repurchases in fiscal 2025 Shares outstanding changed −5.6% over the year, to 108.6M..
What is Regeneron's free cash flow yield?
Regeneron generated $4.1 billion of free cash flow in fiscal 2025, a free cash flow yield of 4.9% on its market value at year-end ($83.8 billion).
What is Regeneron's current ratio?
Regeneron's current ratio was 4.13 at the end of fiscal 2025: current assets were 4.13 times current liabilities.